Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Drexel University

Neither a doctor nor a teaching hospital

Research payments

$1,547,416

414 payments

Through program year 2025, Drexel University is reported as receiving $1,547,416 in research payments, across 414 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $111,548 35
2024 Research $177,424 46
2023 Research $184,800 55
2022 Research $239,709 103
2021 Research $146,574 23
2020 Research $178,261 50
2019 Research $509,101 102

Breakdown

Who paid Research payments · program years 2019–2025
  1. Agios Pharmaceuticals, Inc. $265,794 98 payments
  2. Ucb SA $169,175 14 payments
  3. Pfizer Inc. $160,438 82 payments
  4. American Regent $127,530 6 payments
  5. Gilead Sciences, Inc. $122,454 23 payments
  6. BioMarin Pharmaceutical Inc. $107,423 35 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $86,691 31 payments
  8. Genentech, Inc. $80,459 9 payments
  9. Acumed LLC $64,776 2 payments
  10. Roche Diagnostics Operations, Inc. $44,898 19 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease $265,794 98 payments
  2. Heart_FID $127,530 6 payments
  3. A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallelgroup Multicenter Study With A 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam As Mo $110,353 11 payments
  4. A Translational Understanding of Obesityrelated Phenotypes Using Brain Imaging and Manipulation $83,333 2 payments
  5. A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 $57,536 2 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS) $57,048 18 payments
  7. Both Bone Forearm Fracture Plating, Pre-contoured Radius Plate Fix $48,582 1 payment
  8. Gantenerumab in Early Ad $46,022 4 payments
  9. Rd005495 $44,898 19 payments
  10. A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study with a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety and Tolerability of brivaracetam as Monotherapy in Patients 2 to 25 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy (Phase 2/3) $40,944 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $756 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record